Moderators: ziploc_1 , zmanindc , rafunrafun , golf stud , iryokabu , Number sleven
Search This Board: 
Created: 03/12/2007 10:02:49 PM - Followers: 1083 - Board type: Free - Posts Today: 120

AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote 
Y! Finance AMRN Landing Page 
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page


VASCEPA RELATED LINKS & Outside Organizational News
The EPA Drug Initiative (EPADI)
Vascepa Savings Card Program
FDA Orange Book entry for Vascepa
Vascepa Prescribing Information
Vascepa Marine DTC Patient Brochure
Nissui EPA Synthesis History & Methodology
FDA Approval of Vascepa for the Reduction of Triglyceride Levels ≥ 500mg/dL (26 Jul 2012)
Pure EPA Vascepa Now Available in Half-Gram Capsule Size (25 Oct 2016)
ADA’s 2019 Standards of Medical Care in Diabetes Incorporate Findings from REDUCE-IT (28 Mar 2019)
New 2019 Updates to the European Society of Cardiology and European Atherosclerosis Society’s Guidelines incorporate Reduce-IT (3 Sep 2019)
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl (16 Sep 2019)
Independent Drug-Pricing Assessment Finds Vascepa Cost-Effective (17 Oct 2019)

RELEVANT SOCIAL MEDIA ACCOUNTS
Amarin Instagram - @amarincorp Amarin Twitter - @amarincorp Amarin LinkedIn Amarin ADP Portal - Job Openings Dr. Bhatt Twitter - @DLBHATTMD
TerraPharma Twitter - @TerraPharma1 John Cappello Twitter - @JohnCappello RafunRafun Twitter - @ra_fun K Trivedi Twitter - @GPUWorld  
 

VASCEPA CLINICAL TRIALS + FDA Meetings
Marine & Anchor (Amarin Led)
MARINE Study meets primary endpoints(29 Nov 2010)
ANCHOR Trial meets all Primary and Secondary Endpoints (18 Apr 2011)
Additional Inflammatory Marker Data from Marine and Anchor (22 Jan 2013)
New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in Marine and Anchor (8 April 2013)
FDA AD-Com Outcome for Anchor sNDA (16 October 2013)
FDA delays ANCHOR sNDA (20 Dec 2013)
Presentation of MARINE and ANCHOR analyses at AHA showing significant reduction of remnant-like particle cholesterol (17 Nov 2014)
Marine & Anchor Key Summaries (2017)
Vascepa showed reductions in potentially atherogenic lipids and inflammatory markers – Anchor post-hoc (12 Mar 2018)

REDUCE-IT (Amarin Led)
NIH Clinical Trial Page
Amarin Announces Dosing of First Patient in REDUCE-IT (7 Dec 2011)
Amarin and FDA Reaffirm Concurrence on REDUCE-IT through SPA Agreement Amendment (4 Aug 2016)
Amarin Randomizes Final Patient into REDUCE-IT (31 Aug 2016)
REDUCE-IT to Continue As Planned at Recommendation of Independent Data Monitoring Committee (14 Aug 2017)
REDUCE-IT Meets Primary Endpoint (24 Sep 2018)
REDUCE-IT Displayed 25% RRR in 5-Point MACE (10 Nov 2018)
REDUCE-IT NEJM Article(3 Jan 2019)
REDUCE-IT showed 30% reduction in total Cardiovascular events (18 Mar 2019)
Amarin submits sNDA seeking new indication based on REDUCE-IT (28 Mar 2019)
FDA Grants Priority Review for Vascepa sNDA (29 May 2019)
Amarin Notified of Ad-Com Meeting Planned for Nov 2019 (8 Aug 2019)
REDUCE-IT USA-specific Results released (11 Nov 2019)
FDA AD-Com Outcome for REDUCE-IT sNDA (14 Nov 2019)
REDUCE-IT related data presented at 2019 AHA (18 Nov 2019)


PARTNERSHIPS / OVERSEAS
Amarin and Eddingpharm announce agreement for Vascepa in China (26 Feb 2015)
Amarin and HLS announce agreement for Vascepa in Canada (25 Sep 2017)
Commencement of Vascepa Clinical Development in China (17 Jan 2018)
Biologix and Amarin announce approval of Vascepa in Lebanon for patients with Triglyceride Levels ≥ 500mg/dL (21 Mar 2018)
Amarin & Mochida Announce Collaboration on Future Development of EPA-Based Drug Products and Indications (12 Jun 2018)
Biologix and Amarin announce approval of Vascepa in UAE for patients with Triglyceride Levels ≥ 500mg/dL (26 Jul 2018)
Vascepa granted Priority Review from Health Canada New Drug Submission, anticipated to be filed in April 2019 by HLS (29 Mar 2019)
HLS files New Drug Submission for Vascepa with Health Canada (29 April 2019)


EPA Trials for other indications
Section Pending

Non-Vascepa (AMR-101) Amarin Trials
Section Pending

 

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#386772
Number 1 Incompetent Management no tweeter account hayward 08/19/2022 09:28:35 PM
#386771
skip/bioinvestor i agree. Germany has always been Laurent Maldague 08/19/2022 09:26:09 PM
#386770
Well … glad to see you’re finding some Whalatane 08/19/2022 09:10:48 PM
#386769
And the Covid trials keep coming https://assets.researchsquare.com/files/rs-19 Whalatane 08/19/2022 09:06:40 PM
#386768
Zip. Interesting question you raise there What’s Whalatane 08/19/2022 08:58:22 PM
#386767
Lets see one guy wants to tell me ralphey 08/19/2022 08:49:30 PM
#386766
req ralphey 08/19/2022 08:49:29 PM
#386765
IW - nice try. In your last post FlyFishingStocks 08/19/2022 08:23:23 PM
#386763
FFS, Oh well I told you my luck iwanderer 08/19/2022 07:30:44 PM
#386762
BIO..."Germany has been known to offer 50% or ziploc_1 08/19/2022 07:28:11 PM
#386761
On the other hand: If a non-manufactured sponsor CaptBeer 08/19/2022 07:08:58 PM
#386760
Capt. What does a bottle of V Whalatane 08/19/2022 07:05:18 PM
#386759
Oh wait, Capt I stand to be corrected. BioInvestor3 08/19/2022 07:02:24 PM
#386758
Bio. The EU is heading into a recession Whalatane 08/19/2022 07:00:52 PM
#386757
Just want to put this out there for BioInvestor3 08/19/2022 06:56:24 PM
#386756
There is undoubtedly a narrow range within all CaptBeer 08/19/2022 06:55:53 PM
#386755
Bio. MITIGATE is high risk for AMRN Whalatane 08/19/2022 06:53:14 PM
#386754
If they thought it would a game changer BioInvestor3 08/19/2022 06:49:04 PM
#386753
Mitigate trial: top-line data by mid-September, complete data north40000 08/19/2022 06:48:40 PM
#386752
They never talk about studies in which they CaptBeer 08/19/2022 06:44:10 PM
#386751
Assuming that today Round #4 was completed and CaptBeer 08/19/2022 06:41:35 PM
#386750
It’s always something. It never does get any wodehouse 08/19/2022 06:39:19 PM
#386749
No, Sweden was first and they were at BioInvestor3 08/19/2022 06:38:38 PM
#386748
Good Question. I'll find out CaptBeer 08/19/2022 06:35:37 PM
#386747
It's just my opinion, I don't think those BioInvestor3 08/19/2022 06:34:41 PM
#386746
Capt. Is the Arb board after AHA ? Ideally Whalatane 08/19/2022 06:34:08 PM
#386745
Bio. U sell and generate revenue based Whalatane 08/19/2022 06:25:42 PM
#386744
Weekend' - Suggest we send the guys jasbg 08/19/2022 06:18:24 PM
#386743
No doubt. Germany is in a bad way. CaptBeer 08/19/2022 06:18:24 PM
#386742
Haha. Very funny. That’s not what I meant RobinF 08/19/2022 06:16:40 PM
#386741
Was there not discussion this past week about Monk44 08/19/2022 06:14:42 PM
#386740
That is true. Furthermore, a new law pending CaptBeer 08/19/2022 06:12:18 PM
#386739
Capt. Doubt that’s what happened. Germany would have Whalatane 08/19/2022 06:11:57 PM
#386738
Thanks. I’ll peruse when I can. Need to tke458 08/19/2022 06:07:56 PM
#386737
Here's your chance to find those answers: CaptBeer 08/19/2022 06:06:56 PM
#386736
Study. Good call on your part . I Whalatane 08/19/2022 06:04:49 PM
#386735
Oh yeah, I forgot about Denner. I BioInvestor3 08/19/2022 06:04:23 PM
#386734
No, never followed those trials. At the BioInvestor3 08/19/2022 05:52:15 PM
#386733
Kiwi, I agree. Interesting comparison: AMRN vs FlyFishingStocks 08/19/2022 05:46:50 PM
#386732
If they accept what Germany is offering it BioInvestor3 08/19/2022 05:46:45 PM
#386731
Thanks for clarifying. That’s what I figured but tke458 08/19/2022 05:43:07 PM
#386730
IRCC, The "Free-Pricing" point for VAZKEPA in the CaptBeer 08/19/2022 05:42:53 PM
#386729
Lets give them some credit…. They did release bad Toddrobertking 08/19/2022 05:41:45 PM
#386728
They settled on a price with the UK sts66 08/19/2022 05:41:10 PM
#386727
Same here, that Q2 cc was very telling. BioInvestor3 08/19/2022 05:39:23 PM
#386726
But AMRN did not get it's 12 month sts66 08/19/2022 05:39:07 PM
#386725
AMRN fucks up again - they're closing Germany sts66 08/19/2022 05:36:10 PM
#386724
The arbitration sets a price, so the answer BioInvestor3 08/19/2022 05:32:32 PM
#386723
No new trial data would probably move the BioInvestor3 08/19/2022 05:29:31 PM
#386722
Anyone happen to know the percentage of arbitration tke458 08/19/2022 05:26:56 PM
Post Subject